- Home
- NSPR vs CNTB Comparison
NSPR vs CNTB Comparison
Compare NSPR & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NSPR
- CNTB
- Stock Information
- Founded
- NSPR 2005
- CNTB 2012
- Country
- NSPR United States
- CNTB United States
- Employees
- NSPR N/A
- CNTB N/A
- Industry
- NSPR Medical/Dental Instruments
- CNTB Biotechnology: Pharmaceutical Preparations
- Sector
- NSPR Health Care
- CNTB Health Care
- Exchange
- NSPR Nasdaq
- CNTB Nasdaq
- Market Cap
- NSPR 99.7M
- CNTB 90.3M
- IPO Year
- NSPR N/A
- CNTB 2021
- Fundamental
- Price
- NSPR $2.35
- CNTB $1.75
- Analyst Decision
- NSPR Strong Buy
- CNTB Strong Buy
- Analyst Count
- NSPR 2
- CNTB 2
- Target Price
- NSPR $4.50
- CNTB $7.50
- AVG Volume (30 Days)
- NSPR 135.7K
- CNTB 100.0K
- Earning Date
- NSPR 11-11-2025
- CNTB 11-30-2025
- Dividend Yield
- NSPR N/A
- CNTB N/A
- EPS Growth
- NSPR N/A
- CNTB N/A
- EPS
- NSPR N/A
- CNTB N/A
- Revenue
- NSPR $7,066,000.00
- CNTB $1,965,000.00
- Revenue This Year
- NSPR $7.48
- CNTB N/A
- Revenue Next Year
- NSPR $104.39
- CNTB $453,067.90
- P/E Ratio
- NSPR N/A
- CNTB N/A
- Revenue Growth
- NSPR 7.60
- CNTB N/A
- 52 Week Low
- NSPR $1.99
- CNTB $1.23
- 52 Week High
- NSPR $3.80
- CNTB $2.20
- Technical
- Relative Strength Index (RSI)
- NSPR 42.67
- CNTB 49.14
- Support Level
- NSPR $2.30
- CNTB $1.72
- Resistance Level
- NSPR $2.50
- CNTB $1.90
- Average True Range (ATR)
- NSPR 0.09
- CNTB 0.16
- MACD
- NSPR -0.01
- CNTB 0.01
- Stochastic Oscillator
- NSPR 16.98
- CNTB 49.28
About NSPR InspireMD Inc.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.